Mixed trend on the daily chart: above its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up since Aug 10 · below the Ichimoku cloud · RSI 52 · MACD below its signal
None of the 29 investors followed here reported a position in USRM in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a USRM trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for USRM.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | ||
| 2025 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2024 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2023 | -2.1 | 8.5 | -4.5 | -22.0 | -31.6 | 5.8 | -92.7 | 0.0 | 50.0 | -96.7 | 0.0 | 900.0 | −97.9% |
| 2022 | 16.7 | 40.4 | -4.4 | -23.4 | -30.6 | 12.0 | 19.6 | -7.5 | -1.6 | -1.6 | -30.0 | 14.3 | −20.0% |
| 2021 | 134.4 | 60.5 | 8.9 | -24.5 | -34.1 | -38.1 | -12.6 | -3.4 | -14.6 | 3.6 | -15.7 | -38.1 | −50.8% |
| 2020 | 102.9 | -9.9 | 7.8 | -1.4 | -13.2 | 1.7 | -13.3 | -13.5 | -4.4 | 74.4 | -10.0 | 80.7 | +248.6% |
| 2019 | 30.6 | 34.9 | -23.8 | -7.0 | -11.0 | -45.5 | -46.4 | 11.5 | 4.3 | -20.7 | 8.3 | -32.7 | −78.1% |
| 2018 | 33.4 | 21.4 | 65.9 | -32.9 | -44.6 | 0.3 | -26.1 | 20.9 | 1.9 | 1.9 | -24.1 | -22.0 | −44.8% |
| 2017 | 110.3 | 1168.3 | 124.8 | -37.6 | 12.6 | -38.0 | -29.3 | -39.4 | -1.8 | 35.0 | 57.4 | -36.3 | +1387.2% |
| 2016 | -45.1 | -44.0 | -55.4 | -33.3 | -53.1 | -57.9 | 58.2 | -25.6 | -62.4 | -28.6 | -50.0 | -22.0 | −99.8% |
| 2015 | 52.4 | -43.8 | -1.1 | -23.6 | -15.1 | 14.4 | -3.0 | -45.3 | -45.7 | -42.1 | -14.5 | -6.9 | −91.7% |
| 2014 | 50.0 | 26.7 | 135.3 | -43.6 | -4.8 | 12.5 | 2.6 | -16.6 | 7.8 | -19.7 | -22.5 | -32.3 | +5.0% |
| 2013 | 16.7 | 2.9 | 111.1 | 10.3 | -29.1 | -31.0 | -10.7 | -12.6 | -31.3 | 0.0 | -5.5 | -3.8 | −33.3% |
| 2012 | -8.5 | 43.9 | -34.7 | -40.3 | 11.3 | 13.3 | -17.2 | 8.3 | -18.1 | 8.0 | -23.9 | -14.3 | −66.5% |
| 2011 | -21.2 | -23.1 | -5.0 | -26.3 | 27.9 | -55.3 | 71.3 | -48.9 | 0.0 | 14.3 | -25.0 | -25.3 | −86.4% |
| 2010 | -12.2 | -7.7 | 20.0 | 11.1 | -31.3 | -21.8 | -18.6 | -51.4 | 47.0 | 0.0 | 76.0 | -25.0 | −55.4% |
| 2009 | -19.2 | 26.2 | -36.6 | 25.0 | 5.0 | 0.0 | -8.3 | -7.8 | 152.1 | -49.2 | -2.2 | -16.9 | −25.3% |
| 2008 | -11.7 | -6.5 | -15.1 | -10.3 | 75.4 | -17.8 | -36.7 | -35.0 | -40.8 | -1.0 | −78.1% |
No analyst coverage for this instrument.
U.S. Stem Cell, Inc. engages in the research, development, and commercialization of stem cell and regenerative treatments in the United States and internationally. The company develops MyoCell, an autologous muscle stem cell therapy which is preparing for phase II/III clinical trials for the treatment of heart damage in heart failure patients; MyoCell SDF-1, an autologous cell therapy which completed the IND application for the treatment of chronic damage in the heart and enhancement of blood vessel formation; and AdipoCell, a clinical protocol and kit which is preparing for clinical trials for the treatment of chronic ischemic cardiomyopathy. It also offers regenerative medicine solutions to veterinarians; and training programs for physicians to perform bone marrow derived stem cell protocols. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in November 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.